SCHEMBL1953258

SCHEMBL1953258

Cc1c(Cl)c(=O)oc2cc(OP(=O)(O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@@H]3O)ccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.56
ALDH1A1 P00352 6/20 0.56
HPGD P15428 6/20 0.56
GAA P10253 4/20 0.56
HSD17B10 Q99714 2/20 0.56
CA12 O43570 3/20 0.54
CA1 P00915 3/20 0.54
CA4 P22748 3/20 0.54
CA5A P35218 3/20 0.54
CA7 P43166 3/20 0.54
CA5B Q9Y2D0 3/20 0.54
CA3 P07451 1/20 0.54
CYP3A4 P08684 1/20 0.54
CA6 P23280 1/20 0.54
CA9 Q16790 1/20 0.54
CA13 Q8N1Q1 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
CA14 Q9ULX7 1/20 0.54
LMNA P02545 2/20 0.53
ALPL P05186 9/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12549576 1.00 KDM4E (0.56) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL27834681 0.82 KDM4E (0.55) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL1938409 0.81 HSD17B3 (0.67) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL4104045 0.80 KDM4E (0.65) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL3265953 0.80 KDM4E (0.62) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL38663564 0.79 KDM4E (0.70) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL4104048 0.79 KDM4E (0.70) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL12548844 0.76 KDM4E (0.48) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL18284647 0.74 KDM4E (0.76) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL669657 0.74 KDM4E (0.77) KDM4EALDH1A1HPGDGAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110129871-A1 CULTURE MEDIUM ENABLING STAPHYLOCOCCUS AUREUS TO BE DIFFERENTIATED FROM COAGULASE-NEGATIVE STAPHYLOCOCCI BIOMERIEUX (FR) 2011-06-02 US claimed
US-20110129871-A1 CULTURE MEDIUM ENABLING STAPHYLOCOCCUS AUREUS TO BE DIFFERENTIATED FROM COAGULASE-NEGATIVE STAPHYLOCOCCI BIOMERIEUX (FR) 2011-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110129871-A1 CULTURE MEDIUM ENABLING STAPHYLOCOCCUS AUREUS TO BE DIFFERENTIATED FROM COAGULASE-NEGATIVE STAPHYLOCOCCI PLA2G12A, PLA2G3, PLA2G12B KDM4E 3560/4885ALDH1A1 4067/4885HPGD 860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.